Sorrento Therapeutics (NASDAQ: SRNE), a clinical-stage, antibody-centric biopharmaceutical company, received the go-ahead to commence the Phase 1 clinical trial for allogeneic anti-CD38 Dimeric Antigen Receptor (DAR)-T cell therapy. The U.S. Food and Drug Administration (FDA) has authorized Sorrento’s Investigational New Drug (IND) application for its proprietary DAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. Following the FDA approval, shares of Sorrento closed 1.6% higher on Monday. Sorrento has designed DAR-T technology to provide a significant advancement to the timeliness and potency of myeloma treatments. The treatment targets patient populations who have already undergone multiple rounds of chemotherapy, and are suffering from persistent disease, the company said.
https://www.tipranks.com/news/sorrento-gets-fed-go-ahead-to-test-myeloma-med?utm_source=advfn.com&utm_medium=referral
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Sorrento Therapeutics Charts.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Sorrento Therapeutics Charts.